MoH stops sale of high blood pressure drug over cancer concerns

KUALA LUMPUR, 25 Nov 2018: 

A company that supplies and sells products containing losartan has been ordered to stop doing so, says Health director-general Datuk Noor Hisham Abdullah.

He said in a statement the order would be effective until the company could prove its products do not contain impurity N-nitrosodiethylamine (NDEA).

“There’s only one losartan product in Malaysia and that’s Lostad HCT 50/12.5 mg film-coated tablets. Products containing NDEA may cause cancer to consumers in the long run.

“Patients taking this medicine are advised not to abruptly stop taking it and to seek advice from medical professionals,” he said, adding that the public should use products registered with the Drug Control Authorities.

Products containing losartan and valsartan are used to treat patients with high blood pressure.

The statement was issued following a recall notice by the United States Food and Drug Administration of products containing active valsartan and losartan ingredients due to the presence of NDEA.

Dr Noor Hisham said the public can check the registration status of products via the National Pharmacy Regulatory Agency website at www.npra.gov.my or through the NPRA Product Status app downloaded from Google Play.

– Bernama

Leave a Reply